Dosage Form Transition Bridging

Dosage form transition bridging evaluates pharmacokinetic differences between oral tablets, capsules, injections, and topical formulations ensuring equivalent therapeutic exposure. Bioequivalence studies compare modified-release to immediate-release formulations. Intra-subject variability assessment determines whether formulation changes necessitate dose adjustments. Population pharmacokinetic analysis characterises dosage form effects across heterogeneous patients.

Regulatory submissions incorporating bridging data support dosage form changes. Clinical outcomes monitoring detects inadequate bioavailability from formulation transitions. Therapeutic drug monitoring guides dose adjustments maintaining therapeutic levels. Patent considerations sometimes prompt formulation changes extending market exclusivity. Post-approval monitoring confirms clinical equivalence after implementation.